REGENXBIO Inc.·4

Aug 5, 6:39 PM ET

KARABELAS ARGERIS N 4

4 · REGENXBIO Inc. · Filed Aug 5, 2024

Insider Transaction Report

Form 4
Period: 2024-08-01
Transactions
  • Exercise/Conversion

    Common Stock

    2024-08-01$3.76/sh+10,000$37,60021,286 total
  • Sale

    Common Stock

    2024-08-01$14.59/sh400$5,83411,386 total
  • Sale

    Common Stock

    2024-08-01$13.45/sh9,600$129,12011,786 total
  • Sale

    Common Stock

    2024-08-01$15.00/sh100$1,50011,286 total
  • Exercise/Conversion

    Stock Options (Right to Buy)

    2024-08-0110,00020,000 total
    Exercise: $3.76Exp: 2025-05-19Common Stock (10,000 underlying)
  • Exercise/Conversion

    Common Stock

    2024-08-01$12.74/sh+100$1,27421,386 total
  • Exercise/Conversion

    Stock Options (Right to Buy)

    2024-08-011001,400 total
    Exercise: $12.74Exp: 2026-06-01Common Stock (100 underlying)
Footnotes (5)
  • [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan.
  • [F2]This transaction was executed in multiple trades at prices ranging from $13.20 to $14.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F3]This transaction was executed in multiple trades at prices ranging from $14.44 to $14.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F4]The previously granted option, representing a right to purchase a total of 12,500 shares, became exercisable as follows: the option vested in 12 equal monthly installments following June 1, 2016.
  • [F5]The previously granted option, representing a right to purchase a total of 40,000 shares, became exercisable as follows: 25% of the shares subject to the option vested on May 19, 2015, and the balance vested equal installments over the next 24 months.

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT